David R. Fogelman
Merck & Co., Inc., Rahway, NJ, USA (United States)
ORCID: 0000-0002-4063-189XPilot corpus only
This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.
Indexed papers
Papers
Driven by 6 papers. Top paper: “Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors”.
Suyu Liu, Arvind Dasari, David R. Fogelman, Priya Bhosale, Armeen Mahvash +21 more
Laura Prakash, Giuseppe Malleo, Andrea Caravati, Gauri R. Varadhachary, David R. Fogelman +13 more
Clifton D. Fuller, Vivek Verma, W. Ian P. Mainwaring, Andres F. Espinoza, Austin B. Miller +10 more
Jane E. Rogers, Kenneth R. Hess, Robert A. Wolff, Gauri R. Varadhachary, Milind Javle +7 more
Thomas LaFramboise, Michael S. Lee, Cathy Eng, David R. Fogelman, Stanley R. Hamilton +14 more
S. Greg Call, Helen J. Huang, A.L. Stuckett, Kiran Madwani, Abha Adat +16 more